We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Stock Moves -0.18%: What You Should Know
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed the latest trading day at $39.11, indicating a -0.18% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily loss of 1.18%. Meanwhile, the Dow experienced a drop of 0.76%, and the technology-dominated Nasdaq saw a decrease of 1.76%.
The the stock of company has fallen by 16.87% in the past month, lagging the Medical sector's loss of 5.07% and the S&P 500's loss of 3.35%.
The investment community will be paying close attention to the earnings performance of CRISPR Therapeutics AG in its upcoming release. The company's earnings per share (EPS) are projected to be -$1.98, reflecting a 11.61% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $20.67 million, up 22863.33% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$4.66 per share and a revenue of $271.11 million, indicating changes of +44.26% and +22530.49%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for CRISPR Therapeutics AG. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 6.36% higher. Currently, CRISPR Therapeutics AG is carrying a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 65, this industry ranks in the top 26% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Stock Moves -0.18%: What You Should Know
CRISPR Therapeutics AG (CRSP - Free Report) closed the latest trading day at $39.11, indicating a -0.18% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily loss of 1.18%. Meanwhile, the Dow experienced a drop of 0.76%, and the technology-dominated Nasdaq saw a decrease of 1.76%.
The the stock of company has fallen by 16.87% in the past month, lagging the Medical sector's loss of 5.07% and the S&P 500's loss of 3.35%.
The investment community will be paying close attention to the earnings performance of CRISPR Therapeutics AG in its upcoming release. The company's earnings per share (EPS) are projected to be -$1.98, reflecting a 11.61% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $20.67 million, up 22863.33% from the prior-year quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$4.66 per share and a revenue of $271.11 million, indicating changes of +44.26% and +22530.49%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for CRISPR Therapeutics AG. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Within the past 30 days, our consensus EPS projection has moved 6.36% higher. Currently, CRISPR Therapeutics AG is carrying a Zacks Rank of #2 (Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 65, this industry ranks in the top 26% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.